Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02546284

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML) Clinical Trial

Official title:
A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)

Clinical Trial Summary

This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity.

Clinical Trial Description

The purpose of the study is to examine the safety and determine the recommended Phase 2 dose of lenzilumab when administered to subjects with previously treated CMML who meet the entry criteria. Study will begin enrollment in July 2016. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02546284
Study type Interventional
Source Humanigen, Inc.
Contact
Status Completed
Phase Phase 1
Start date July 2016
Completion date February 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00528983 - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Phase 1
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Completed NCT01736683 - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Phase 2
Terminated NCT02147873 - Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Phase 2
Terminated NCT02749708 - Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Phase 1
Recruiting NCT04409639 - Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations Phase 2
Active, not recruiting NCT04603001 - Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Phase 1
Completed NCT01842646 - Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT01613976 - A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients Phase 1
Terminated NCT00664677 - Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia Phase 1
Recruiting NCT03922100 - Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Phase 1/Phase 2
Completed NCT05048498 - Pharmacokinetics, Tolerability and Safety of NEX-18a Phase 1
Withdrawn NCT04217720 - SNS-301 Monotherapy in High Risk MDS and CMML Phase 2